Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tectonic Therapeutic, Inc. (TECX : NSDQ)

• Company Description    Tectonic Therapeutic Inc. is a biotechnology company developing GPCR -targeted therapeutic proteins. Tectonic Therapeutic Inc., formerly known as AVROBIO Inc., is based in CAMBRIDGE, Mass. Number of Employees: 51

• Price / Volume Information    Yesterday's Closing Price: $23.45 Daily Weekly Monthly 20 Day Moving Average: 569,121 shares Shares Outstanding: 18.78 (millions) Market Capitalization: $440.31 (millions) Beta: 3.75 52 Week High: $27.33 52 Week Low: $13.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.31% 18.33% 12 Week 17.72% 17.58% Year To Date 12.42% 11.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 490 ARSENAL WAY SUITE 210 - WATERTOWN,MA 02472 USA ph: 339-666-3320 fax: - daniel@lifesciadvisors.com http://www.tectonictx.com

• General Corporate Information    Officers Alise Reicin - President; Chief Executive Officer and Director Daniel Lochner - Chief Financial Officer Terrance McGuire - Director Stefan Vitorovic - Director Timothy A. Springer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 878972108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 18.78 Most Recent Split Date: (:1) Beta: 3.75 Market Capitalization: $440.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.75 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -22.62% vs. Previous Quarter: -0.98% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - -26.88 09/30/25 - -27.11 06/30/25 - -30.13 ROA 12/31/25 - -25.83 09/30/25 - -25.88 06/30/25 - -28.33 Current Ratio 12/31/25 - 26.62 09/30/25 - 29.15 06/30/25 - 25.60 Quick Ratio 12/31/25 - 26.63 09/30/25 - 29.15 06/30/25 - 25.60 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - 13.43 09/30/25 - 14.30 06/30/25 - 15.20 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.02 09/30/25 - 0.04 06/30/25 - 0.07

Powered by Zacks Investment Research ©